Pseudohypoxia: Difference between revisions

Content deleted Content added

Inline

Revision as of 20:42, 10 February 2018

Pseudohypoxia refers to increased cytosolic ratio of free NAD to NADH in cells.^[1] Research has shown that declining levels of NAD+ during aging cause pseudohypoxia, and that raising nuclear NAD+ in old mice reverses pseudohypoxia and metabolic dysfunction, thus reversing the aging process.^[2] It is expected that human NAD trials will begin in 2014.^[3]

References

^ [1] Diabetes Magazine: Hyperglycemic Pseudohypoxia and Diabetic Complications, March 12, 1993
^ [2] Declining NAD+ Induces a Pseudohypoxic State Disrupting Nuclear-Mitochondrial Communication during Aging, Cell, Dec 2013
^ [3] Guardian Newspaper - Online, Dec 2013

This article about a disease, disorder, or medical condition is a stub. You can help Wikipedia by expanding it.

[1] [1] Diabetes Magazine: Hyperglycemic Pseudohypoxia and Diabetic Complications, March 12, 1993

[2] [2] Declining NAD+ Induces a Pseudohypoxic State Disrupting Nuclear-Mitochondrial Communication during Aging, Cell, Dec 2013

[3] [3] Guardian Newspaper - Online, Dec 2013

[1]

[2]

[3]

Revision as of 09:16, 17 January 2018 edit 145.116.42.210 (talk) No edit summary ← Previous edit		Revision as of 20:42, 10 February 2018 edit undo Rodw (talk \| contribs) Autopatrolled, Event coordinators, Extended confirmed users, New page reviewers, Pending changes reviewers, Rollbackers 742,655 edits m Disambiguated: NAD → Nicotinamide adenine dinucleotide Tag: Dispenser [1.0] Next edit →
Line 1:		Line 1:
	'''Pseudohypoxia''' refers to increased [[cytosol]]ic ratio of free [[NAD]] to [[Nicotinamide adenine dinucleotide\|NADH]] in cells.<ref>[http://diabetes.diabetesjournals.org/content/42/6/801] Diabetes Magazine: Hyperglycemic Pseudohypoxia and Diabetic Complications, March 12, 1993</ref>		'''Pseudohypoxia''' refers to increased [[cytosol]]ic ratio of free [[Nicotinamide adenine dinucleotide\|NAD]] to [[Nicotinamide adenine dinucleotide\|NADH]] in cells.<ref>[http://diabetes.diabetesjournals.org/content/42/6/801] Diabetes Magazine: Hyperglycemic Pseudohypoxia and Diabetic Complications, March 12, 1993</ref>
	Research has shown that declining levels of NAD+ during aging cause pseudohypoxia, and that raising nuclear NAD+ in old mice reverses pseudohypoxia and metabolic dysfunction, thus reversing the aging process.<ref>[http://www.cell.com/abstract/S0092-8674%2813%2901521-3] Declining NAD+ Induces a Pseudohypoxic State Disrupting Nuclear-Mitochondrial Communication during Aging, Cell, Dec 2013</ref> It is expected that human NAD trials will begin in 2014.<ref>[https://www.theguardian.com/science/2013/dec/20/anti-ageing-human-trials?CMP=EMCNEWEML6619I2] Guardian Newspaper - Online, Dec 2013</ref>		Research has shown that declining levels of NAD+ during aging cause pseudohypoxia, and that raising nuclear NAD+ in old mice reverses pseudohypoxia and metabolic dysfunction, thus reversing the aging process.<ref>[http://www.cell.com/abstract/S0092-8674%2813%2901521-3] Declining NAD+ Induces a Pseudohypoxic State Disrupting Nuclear-Mitochondrial Communication during Aging, Cell, Dec 2013</ref> It is expected that human NAD trials will begin in 2014.<ref>[https://www.theguardian.com/science/2013/dec/20/anti-ageing-human-trials?CMP=EMCNEWEML6619I2] Guardian Newspaper - Online, Dec 2013</ref>

Revision as of 20:42, 10 February 2018

See also

References